We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Bioelectronics Corp (PK) | USOTC:BIEL | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00005 | 50.00% | 0.00015 | 0.0001 | 0.0002 | 0.0002 | 0.0001 | 0.0002 | 8,682,565 | 20:54:33 |
FREDERICK, Md., May 14, 2014 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced drug-free consumer medical devices, today announced more detail on the interim results of a randomized, double blind, placebo controlled trial on osteoarthritis of the knee (knee pain) using ActiPatch® Therapy. The interim results are now published online at the EULAR (European League against Arthritis) conference website at https://b-com.mci-group.com/AbstractList/EULAR2014.aspx and search for abstract #: AB0777.
"Arthritis is the major cause of disability in the US affecting 52.5 million adults. Osteoarthritis of the knee is the most common musculoskeletal pain and disability condition. Therefore we are extremely pleased by the results of Dr. Gianluca Bagnato's clinical study," commented Ian Rawe, Ph.D. Director of Research, BioElectronics. Dr. Rawe noted that the study looked at three important measures associated with Osteoarthritis, these being pain, ease of movement and overall patient quality of life. "Importantly the study results show significant improvement in all three measures for the group wearing the active ActiPatch device relative to the group wearing the non-active device. We take these results as strong support for our contention that our affordable innovative drug-free technology can greatly reduce disabilities, physician office visits, and the reliance on drugs for chronic pain."
ActiPatch® Musculoskeletal Pain Therapy devices are readily available, over-the-counter outside of the US, for approximately $30.00, or $0.04 per hour of therapy.
The specific four weeks of ActiPatch® Therapy showed the following:
[*WOMAC - Western Ontario and McMaster Universities Osteoarthritis Index]
Other Clinical Research
BioElectronics is conducting a series of clinical research studies using its medical devices. Details can be found at http://www.bielcorp.com/clinical-evidence/ along with details of previously completed and published clinical trials.
About BioElectronics Corporation
BioElectronics Corporation is a leader in biophysics and the maker of an industry leading family of disposable, drug-free, anti-inflammatory devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy; and HealFast® Therapy for dogs, cats and horses. For more information, please visit www.bielcorp.com.
Contact:
Paul Knopick
940.262.3584
pknopick@eandecommunications.com
SOURCE BioElectronics Corporation
Copyright 2014 PR Newswire
1 Year Bioelectronics (PK) Chart |
1 Month Bioelectronics (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions